MedTrace Logo

Frontline of ASCT in High-risk DLBCL

NCT05831865 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 175

Last updated 2023-05-06

No results posted yet for this study

Summary

The role of frontline therapy of autologous stem cell transplant (ASCT) in diffuse large B-cell lymphoma (DLBCL) is controversial. The investigators aim to conduct this prospective study to observe the efficacy and safety of ASCT as frontline therapy in DLBCL patients with high-risk disease, defined by an International Prognostic Index (IPI) score equal to or greater than three.

Conditions

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    collaborator OTHER

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Jin Lu, M.D. · Peking University People's Hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-03
Primary Completion
2025-04-27
Completion
2027-04-27

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05831865 on ClinicalTrials.gov